Use of transient elastography in patients with HIV–HCV coinfection: A systematic review and meta-analysis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 10, 2016, Pages 1684-1693

  Njei, Basile ^a   McCarty, Thomas R ^a   Luk, Jeffrey ^a   Ewelukwa, Oforbuike ^b   Ditah, Ivo ^c   Lim, Joseph K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

elastography; fibrosis; HCV; hepatitis; HIV

Indexed keywords

ARTICLE; CD4 LYMPHOCYTE COUNT; COCHRANE LIBRARY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ELASTOGRAPHY; EMBASE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER STIFFNESS; MEDLINE; META ANALYSIS; MIXED INFECTION; PRIORITY JOURNAL; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TRANSIENT ELASTOGRAPHY; WEB OF SCIENCE; COMPLICATION; DIAGNOSTIC IMAGING; LIVER CIRRHOSIS; PROCEDURES; VIROLOGY;

COINFECTION; ELASTICITY IMAGING TECHNIQUES; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; SENSITIVITY AND SPECIFICITY;

EID: 85002251358     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13337     Document Type: Article

References (40)

1. European Association for Study of L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J. Hepatol. 2014; 60: 392–420.
2. Parkes J, Roderick P, Harris S et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59: 1245–51.
3. Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62: 932–54.
4. HIV/AIDS and Viral Hepatitis. Viral hepatitis - CDC recommendations for specific populations and settings. n.d. http://www.cdc.gov/hepatitis/Populations/HIV.htm. Accessed 16 January 2016.
5. Puoti M, Moioli MC, Travi G, Rossotti R. The burden of liver disease in human immunodeficiency virus-infected patients. Semin. Liver Dis. 2012; 32: 103–13.
6. Konerman MA, Mehta SH, Sutcliffe CG et al. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology 2014; 59: 767–75.
7. Vallet-Pichard A, Mallet V, Pol S. Nonalcoholic fatty liver disease and HIV infection. Semin. Liver Dis. 2012; 32: 158–66.
8. Pineda JA, Romero-Gomez M, Diaz-Garcia F et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005; 41: 779–89.
9. Van Thiel DH, Gavaler JS, Wright H, Tzakis A. Liver biopsy. Its safety and complications as seen at a liver transplant center. Transplantation 1993; 55: 1087–90.
10. Crossan C, Tsochatzis EA, Longworth L et al. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol. Assess. 2015; 19: 1–409 v-vi.
11. Ngo Y, Munteanu M, Messous D et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin. Chem. 2006; 52: 1887–96.
12. Vergniol J, Foucher J, Terrebonne E et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970–9 9 e1-3.
13. Friedrich-Rust M, Ong MF, Martens S et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960–74.
14. Tsochatzis EA, Bosch J, Burroughs AK. New therapeutic paradigm for patients with cirrhosis. Hepatology 2012; 56: 1983–92.
15. Tsochatzis EA, Castera L. Assessing liver disease in HIV–HCV coinfected patients. Curr. Opin. HIV AIDS 2015; 10: 316–22.
16. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat. Med. 2002; 21: 1559–73.
17. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med. Res. Methodol. 2003; 3: 25.
18. Fagan TJ. Letter: Nomogram for Bayes theorem. N. Engl. J. Med. 1975; 293: 257.
19. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J. Clin. Epidemiol. 2005; 58: 882–93.
20. Macaskill P, Gatsonis C, Deeks JJ, Harbord RM, Takwoingi Y. Analysing and presenting results. In: Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy: The Cochrane Collaboration, 2010; 46–47.
21. Castera L, Winnock M, Pambrun E et al. Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration. HIV Medicine 2014; 15: 30–9.
22. de Ledinghen V, Douvin C, Kettaneh A et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J.Acquir. Immune Defic. Syndr. 2006; 41: 175–9.
23. Vergara S, Macias J, Rivero A et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2007; 45: 969–74.
24. Macias J, Recio E, Vispo E et al. Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patients. J. Hepatol. 2008; 49: 916–22.
25. Sanchez-Conde M, Montes-Ramirez ML, Miralles P et al. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J. Viral Hepatitis 2010; 17: 280–6.
26. Kirk GD, Astemborski J, Mehta SH et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV–hepatitis C virus coinfection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009; 48: 963–72.
27. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15–20.
28. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289–93.
29. Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317–25.
30. Kelleher TB, Mehta SH, Bhaskar R et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J. Hepatol. 2005; 43: 78–84.
31. Cales P, Halfon P, Batisse D et al. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. J. Hepatol. 2010; 53: 238–44.
32. Parkes J, Guha IN, Harris S, Rosenberg WM, Roderick PJ. Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease. Comparative Hepatology 2012; 11: 5.
33. Saito H, Tada S, Nakamoto N et al. Efficacy of non-invasive elastometry on staging of hepatic fibrosis. Hepatology research: the official Journal of the Japan Society of Hepatology 2004; 29: 97–103.
34. Naggie S, Cooper C, Saag M et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N. Engl. J. Med. 2015; 373: 705–13.
35. Sulkowski MS, Eron JJ, Wyles D et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. Jama 2015; 313: 1223–31.
36. Wyles DL, Ruane PJ, Sulkowski MS et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N. Engl. J. Med. 2015; 373: 714–25.
37. Rockstroh JK, Nelson M, Katlama C et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. The lancet HIV 2015; 2: e319–27.
38. Fraquelli M, Rigamonti C, Casazza G et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56: 968–73.
39. Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N. Engl. J. Med. 1978; 299: 926–30.
40. de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J. Hepatology 2015; 63: 743–52.